Moleculin Biotech, Inc. — Form S-1
Filed July 29, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 28/100
What the filing says
Moleculin Biotech filed Form S-1 exhibits for a registered direct offering managed by Roth Capital Partners LLC. The offering includes common shares (up to 4,566,210), pre-funded warrants, and Series I warrants (up to 13,698,630). Roth receives 7% of gross proceeds plus up to $100k expenses. Registration became effective [date redacted]. The blank dollar amount and missing pricing terms prevent precise valuation, but warrant structure suggests meaningful dilution.
Why this rating
For $8.8M market-cap company, fundraising is operationally necessary but dilutive. Blank dollar amount prevents concrete analysis. Warrant overhang (300% of shares) typical of distressed biotech but not unusual. No change to operations.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.